Phase II study of combination therapy with S-1 plus cetuximab in patients with EGFR positive KRAS wild type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine(KSCC0901).
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2016
At a glance
- Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 11 Sep 2016 Status changed from active, no longer recruiting to completed.
- 13 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 22 Oct 2009 Status changed from not yet recruiting to recruiting University Hospital Medical Information Network - Japan.